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ABSTRACT 
Introduction: The treatment of some psychopathological dimensions of schizophrenia (e.g. 
negative and depressive symptoms) is still challenging for the modest efficacy of atypical 
antipsychotics. Among pharmacological alternatives, augmentative Selective Serotonin 
Reuptake Inhibitors (SSRIs) to antipsychotics are frequently prescribed in clinical practice to 
improve negative/depressive symptoms of schizophrenia patients, however the data about the 
efficacy of these molecules on negative, depressive and obsessive-compulsive symptoms of 
schizophrenia are contrasting. 
Areas Covered: Res arch using the main database sources has been conducted to obtain 
an overview of the use and efficacy of SSRIs in schizophrenia. 
Expert Opinion: Data are too scanty to draw definitive recommendations. In a 
preliminary way, it can be said that available data do not show effectiveness of SSRIs on 
depressive symptoms of schizophrenia. Regarding negative symptoms, studies are contrasting, 
but paroxetine appears to be the most effective compound among SSRIs. Despite limited data, 
SSRIs appear to be useful for the treatment of obsessive-compulsive symptoms of 
schizophrenia, particularly fluvoxamine. Close clinical and pharmacological monitoring is 
needed in case of concomitant administration of antipsychotics and antidepressants for potential 
serious side effects and influence on plasma drug dosages 
 
Keywords: Selective Serotonin Reuptake Inhibitors (SSRIs), schizophrenia, negative 
symptoms, depression, obsessive-compulsive symptoms 
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Article highlights 
• Atypical antipsychotics have a modest effect on negative and depressive symptoms of 
schizophrenia 
•  Antidepressants, including SSRIs, are prescribed for the treatment of negative, 
depressive, obsessive-compulsive symptoms of schizophrenia, despite the current 
contrasting data about their efficacy 
•  Studies with small samples and the potential dangerous sides effects of 
antipsychotic/SSRI combination prevent from recommending the use of SSRIs for 
schizophrenia treatment 
• Available data indicate that SSRIs have no effect on depressive symptoms of 
schizophrenia, but most studies are underpowered 
• SSRIs have a doubtful effect on negative symptoms of schizophrenia: paroxetine might 
be more effective than other compounds, but currently head-to-head double-blind trials are 
lacking 
• Fluvoxamine might be useful for the treatment of obsessive-compulsive symptoms, but 
data with other SSRIs are scanty and the positive data have to be replicated by further 
double-blind controlled studies and meta-analytical approaches 
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1. INTRODUCTION 
Schizophrenia is a highly disabling disorder with a heterogeneous clinical presentation [1]. 
Different factors have been associated with poor outcome including predominant negative and 
cognitive symptoms [2]. All antipsychotics have showed efficacy in improving positive 
symptoms (delusions and hallucinations of schizophrenia patients) and atypicals were seen as 
promising molecules for all different symptoms of schizophrenia patients [3]. Unfortunately, 
atypical antipsychotics resulted to have only a modest effect on negative symptoms of 
schizophrenia patients (d=0.58), as also confirmed by a recent meta-analysis [4]. In addition, 
atypical antipsychotics have not a clear evidence of efficacy in controlling obsessive-
compulsive [5, 6] and depressive symptoms of schizophrenia [7]. Depressive symptoms impact 
negatively on quality of life, social functioning, overall psychopathology and the severity of 
comorbid medical conditions [8]. In the light of the mentioned unmet needs, several authors 
assessed the effectiveness of alternative compounds (including Selective Serotonin Reuptake 
Inhibitors-SSRIs) for negative, obsessive-compulsive and depressive symptoms of 
schizophrenia patients [9]. Of note, antidepressants, including SSRIs, are frequently prescribed 
both in hospitalized and outpatient schizophrenics [10, 11]. As previous reviews/meta-analyses 
about the use of SSRIs in schizophrenia focussed only on specific symptoms of this disorder 
(e.g. depressive ones) or on specific molecules (e.g. fluvoxamine) [12], purpose of the present 
review is to ascertain the real utility and effectiveness of these antidepressants for the different 
psychopathological dimensions of schizophrenia. In addition, data reported by previous meta-
analyses are discordant: a first paper concluded that there is no global support for an 
improvement in negative symptoms with SSRIs augmentation therapy in schizophrenia [13], 
while a subsequent meta-analysis stated the efficacy of antidepressants and in particular 
fluoxetine in improving negative symptoms of schizophrenia patients [14]. 
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2. METHODS 
A careful search of articles on MEDLINE, PsycINFO, Isi Web of Knowledge, Medscape was 
performed in order to obtain a comprehensive review about the use of SSRIs in schizophrenia. 
Only SSRIs were taken into account, being the most prescribed antidepressants [15] and to 
avoid dissipating information. In addition, the focus on SSRIs has the advantage to give indirect 
information about the role of serotonin on psychopathology of schizophrenia. The words 
“SSRI”, “fluoxetine”, “sertraline”, “citalopram”, “escitalopram”, “fluvoxamine”, “paroxetine” 
have been associated with “schizophrenia”. A manual selection of papers was then performed in 
order to consider only those concerning with the topic of the present article. No restriction 
criteria were established for study design. Exclusion criteria included: 1) animal studies, 2) 
studies with mixed sampl s (e.g. schizophrenia and schizoaffective patients), 3) studies with 
pooled analyses 4) studies assessing the efficacy of SSRIs in ameliorating medical conditions in 
comorbidity with schizophrenia (e.g. weight gain). With regard to the second exclusion 
criterion, studies with < 10% of schizoaffective patients were included, while, with regard to 
the third criterion, the results of single studies of pooled analyses were taken into consideration. 
Only papers in English were included. Two reviewers searched independently eligible articles 
for inclusion. 
Table 1 summarizes the results of the included studies and their effect sizes. In the table the 
studies in which it was impossible to calculate the effect sizes were not included, but they have 
been described in the results. Table 2 reports evaluation of quality of studies according to 
sample size, use of a double-blinded design and administration of at least one specific rating 
scale to assess schizophrenia symptoms in relation to primary study outcomes (e.g. The Calgary 
Depression Scale for Schizophrenia-CDSS with respect to The Montgomery-Asberg Depression 
Rating Scale-MADRS)  
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3. RESULTS 
Six hundred seventy five papers were initially identified, 513 dealt with the topic of the 
review and 69 satisfied the inclusion criteria (Figure 1). Antidepressant treatment was combined 
with antipsychotics in all the selected studies. In the following paragraphs, data about the 
efficacy of each SSRI on different symptoms of schizophrenia will be described and discussed. 
 
4. Fluoxetine 
A first paper reported a decrease of violent incidents and an increase in socialization after 
introduction of adjunctive fluoxetine (20 mg/day) in eight chronic schizophrenia patients [16]. 
Another open-label trial found the effectiveness of fluoxetine (20 mg/day) in improving 
negative and depressive symptoms of 14 antipsychotic-resistant schizophrenia patients [17]. In 
two schizophrenia patients, adjunctive treatment with fluoxetine produced a limited effect on 
compulsive behaviour and a worsening of psychotic symptoms [18], while in other two cases 
fluoxetine resulted to be effective in improving obsessive-compulsive symptoms [19, 20]. In a 
first 12-week double-blind study with 34 chronic schizophrenia patients, fluoxetine (20 mg/day) 
treatment was associated with greater improvement on Scale for the Assessment of Negative 
Symptoms (SANS) and Hamilton Depression Rating Scale (HAM-D) scores than placebo 
without a worsening of psychotic symptoms [21]. An open-label study reported the non-
effectiveness of fluoxetine in improving clinical symptoms of 13 male chronic schizophrenia 
patients [22]. A subsequent 6-week double-blind study failed to demonstrate a greater efficacy 
of fluoxetine 20 mg/day than placebo in ameliorating symptoms of 41 schizophrenia patients 
with the exception of negative ones [23]. Another double-blind placebo-controlled study found 
that, after 8 weeks, there were not significant differences in positive, negative, depressive or 
obsessive-compulsive symptoms between patients given adjunctive fluoxetine or placebo [24]. 
These results were confirmed by a subsequent double-blind study [25]. In contrast, two open-
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label trials reported the effectiveness of fluoxetine in improving respectively obsessive-
compulsive symptoms [26] and general psychopathology of schizophrenia patients [27] 
 
5. Sertraline 
In two schizophrenia patients, sertraline was found to have a beneficial effect in improving 
clozapine-induced obsessive-compulsive symptoms [28, 29]. A 12-week open-label trial 
reported improvement of positive and negative symptoms in 20 chronic schizophrenia patients 
[30]. In contrast, two schizophrenia patients presented no improvement in obsessive compulsive 
symptoms and exacerbation of psychotic symptoms after treatment with sertraline (50 mg/day) 
[31].  Similarly, in another schizophrenia subject, sertraline showed no benefit on depressive 
and cognitive symptoms [32]. An imipramine-controlled study found that sertraline (50 mg/day) 
was faster than the active comparator in improving post-psychotic depressive symptoms of 
schizophrenia patients [33]. In contrast, a double-blind placebo-controlled study failed to 
demonstrate that the addition of sertraline 50 mg/day to antipsychotics had a beneficial effect 
on positive and negative symptoms of chronic schizophrenia inpatients [34]. In addition, in a 
further double-blind placebo-controlled study, treatment with sertraline (50 mg/day) did not 
ameliorate depressive symptoms of 48 remitted schizophrenia patients [35]. Another double-
blind study reported a slight effect of sertraline (100 mg/day) on anxiety/depressive symptoms 
of schizophrenia patients without a significant effect on negative ones [36]. Augmentative 
sertraline (150 mg/day) to olanzapine improved obsessive-compulsive symptoms of two 
schizophrenia patients [37], while augmentative sertraline (50 mg/day) to perphenazine and 
lithium resulted to improve post-psychotic depression of another schizophrenia patient, but with 
a worsening of extrapyramidal side effects (EPS) [38]. Finally, somatic complaints were 
reported to be improved by augmentative sertraline (till 100 mg/day) in a simple schizophrenia 
adolescent [39]. 
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6. Citalopram 
A first double-blind cross-over study demonstrated the efficacy of citalopram (20-60 mg/day) 
over placebo in reducing the number of daily aggressive incidents of 15 violent schizophrenia 
patients [40]; however no greater improvement of scores on rating scales -including the Staff 
Observation Rating Scale (SOAS)- was observed for treatment with citalopram than placebo. A 
following double-blind placebo-controlled 12-week study with 90 chronic schizophrenia 
patients failed to find a superiority of citalopram till 40 mg/day than placebo in improving 
psychopathological symptoms (Positive and Negative Syndrome Scale-PANSS scores), while 
citalopram might increase subjective well-being of these patients (statistically significant 
improvement of Visual Analogue Scale (VAS) scores in citalopram group than placebo)[41]. In 
another study citalopram appeared to alleviate depressive and anxious symptoms of 
schizophrenia patients without improvement of other psychopathological dimensions [42]. 
Similar results were found by a subsequent 10-week single-blind trial, reporting a greater 
improvement on HAM-D/Clinical Global Impression (CGI) scores for citalopram than placebo 
and no statistically significant difference on PANSS scores [43]. A cross-over double-blind 
study failed to find statistically significant differences between citalopram 40 mg/day and 
placebo on any clinical or cognitive measure of 19 schizophrenia patients [44]. A nationwide 
cohort study reported that the current use of citalopram is associated with decreased all-cause 
and suicide mortality in suicidal patients with schizophrenia [45]. Finally two double-blind 
placebo-controlled studies did not find a beneficial effect of citalopram (mean dose 30 mg/day) 
with respect to placebo on negative symptoms of schizophrenia [46, 47]. 
 
7. Escitalopram 
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A first double-blind trial reported no advantage for escitalopram (20 mg/day) than placebo 
for global, negative and depressive symptoms of schizophrenia patients [48]. In contrast, a 
subsequent open-label study found that adjunctive treatment with escitalopram (20 mg/day) 
ameliorated obsessive-compulsive symptoms of schizophrenia patients [49]. Finally, 
escitalopram was reported to be effective in treating antiandrogen-related mood disorder of a 
patient with chronic schizophrenia [50] and in improving negative symptoms of a patient with 
simple schizophrenia [51]. 
 
8. Fluvoxamine 
A preliminary 5-week double-blind placebo-controlled study found fluvoxamine (50-100 
mg/day) to be beneficial in improving negative symptoms of 30 chronic schizophrenia 
inpatients [52]. In the same year, a case of fluvoxamine-induced acute exacerbation was 
reported in a residual schizophrenia patient [53]. In addition, co-administration of fluvoxamine 
with haloperidol was found to worsen cognitive performances of 4 chronic schizophrenia 
patients [54]. In contrast, low-dose (25-50 mg/day) augmentative fluvoxamine to clozapine was 
associated with improvement of negative symptoms in a paranoid schizophrenia patient and in 
an undifferentiated one [55, 56]. In two schizophrenia patients, add-on fluvoxamine (150-200 
mg/day) to antipsychotics caused an improvement of negative symptoms, but a worsening of 
cognitive abilities and exacerbation of psychotic symptoms [57]: these observations were 
confirmed by two subsequent case reports [31]. Clozapine-induced obsessive-compulsive 
symptoms ameliorated in two schizophrenia patients after the introduction of treatment with 
fluvoxamine [58]. In an open-label study, eight schizophrenia patients benefited from 
adjunctive fluvoxamine (25-100 mg/day) to clozapine (improvement of negative and global 
symptoms without psychotic exacerbation) [59]: these results were confirmed by a subsequent 
open trial with 16 schizophrenia patients [60]. A 6-week double-blind study found fluvoxamine 
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(100 mg/day) to be more efficacious than maprotiline in improving negative symptoms of 25 
schizophrenia patients [61]. In addition, fluvoxamine up to 150 mg/day resulted to be effective 
in improving obsessions and negative symptoms of ten neuroleptic-stabilized chronic 
schizophrenia patients [62]. A subsequent 8-week double-blind trial confirmed the efficacy of 
add-on fluvoxamine (100-200 mg/day) to neuroleptics for obsessive symptoms of 
schizophrenia patients, but not for negative ones [63]. An open-label study by the same authors 
further remarked the effectiveness of fluvoxamine (100-200 mg/day) augmentation to 
neuroleptics in reducing obsessive-compulsive symptoms of 16 schizophrenia patients [64]. 
Negative symptoms were improved by fluvoxamine (50-100 mg/day) in a randomized double-
blind placebo controlled study with 52 chronic schizophrenia patients [65]. In addition, 
fluvoxamine 100 mg/day improved obsessive thoughts of a 13-year-old schizophrenia girl [66]. 
In contrast, no changes in depressive symptoms of 8 schizophrenia patients resulted by 
augmentative treatment to olanzapine with fluvoxamine (100 mg/day) [67]. Similar results were 
found with regard to negative symptoms and general psychopathology by a 12-week open-label 
study in which 30 risperidone-resistant schizophrenia patients received add-on fluvoxamine 
(100 mg/day) [68]. On the other hand, augmentative fluvoxamine (50-100 mg/day) to clozapine 
ameliorated global functioning of 12 schizophrenia patients [69]. Fluvoxamine (till 150 mg/day) 
was also reported to improve negative symptoms of 12 haloperidol-treated schizophrenia 
inpatients [70]. Furthermore, obsessive-compulsive symptoms were ameliorated by adjunctive 
treatment with fluvoxamine 200 mg/day) to clozapine in a young schizophrenia boy [71]. A 
single-blind prospective study found that olanzapine plus fluvoxamine (50 mg/day) combined 
treatment improved general psychopathology, but not specifically negative symptoms of 20 
schizophrenia patients [72]. Adjunctive fluvoxamine (50 mg/day) to risperidone (4 mg/day) 
improved cognitive impairment of a young female schizophrenia patient [73], differently from 
other two schizophrenia cases in whom fluvoxamine resulted to be ineffective in ameliorating 
Page 10 of 39
URL: http://mc.manuscriptcentral.com/eoop  Email: Samantha.Wilkinson@informa.com
Expert Opinion On Pharmacotherapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
11 
 
obsessive-compulsive symptoms (250 mg/day) [74,75]. Finally, a double-blind study failed to 
find a superiority of fluvoxamine (150 mg/day) over placebo in improving global, negative, 
cognitive and depressive symptoms of 48 chronic schizophrenia patients [76]. 
  
9. Paroxetine 
Adjunctive paroxetine (50 mg/day) resulted to improve obsessive-compulsive symptoms of a 
chronic schizophrenia woman in treatment with a combination of clozapine (275 mg/day) and 
risperidone (6 mg/day) [77]. Similarly, depressive symptoms of a schizophrenia patient 
improved after adjunctive treatment with paroxetine (20 mg/day) to clozapine [78]. A further 
schizophrenia patient showed a significant improvement in both psychotic and obsessive 
compulsive symptoms by combination of clozapine (200 mg/day) and paroxetine (30 mg/day) 
[79]. A similar improvement on obsessive-compulsive symptoms was observed in another 
schizophrenia case [71]. Eight chronic schizophrenia patients improved negative symptoms 
after a 12-week treatment with paroxetine (30 mg/day) as an add-on therapy to antipsychotics 
[80]. These results were confirmed by a further open-label trial with 12 schizophrenia patients 
treated with a combination of risperidone and paroxetine (10-40 mg/day) [81] and by a double-
blind placebo-controlled study [82]. However, both these studies did not find a significant effect 
of paroxetine on depressive symptoms of schizophrenia patients [82]. In an open-label 
prospective study, the combination of olanzapine plus paroxetine resulted to be less effective 
than the combination of olanzapine plus fluvoxamine in improving negative symptoms of 50 
schizophrenia patients [83]. Finally, Paroxetine (10-20 mg/day) added to aripiprazole did not 
produce significant clinical improvement in 14 schizophrenia patients [84]. 
 
10. CONCLUSION 
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Studies about the use of SSRIs in schizophrenia have focused mainly on negative symptoms 
and depression and to a lesser extent on the general psychopathology and obsessive-compulsive 
symptoms. In contrast, few data were published about the impact of SSRIs on cognitive 
impairment of schizophrenia patients [85, 86]. In addition, with a few exceptions [45], small 
sample sizes of the studies prevent from drawing precise considerations about the effectiveness 
of SSRIs across the different psychopathological dimension of schizophrenia. Finally, the 
studies use different scales for the assessment of the heterogeneous symptoms of schizophrenia 
(e.g. Brief Psychiatric Rating Scale –BPRS- and SANS for negative symptoms) and this makes 
the overall interpretation of the results even more difficult. 
Going into details, with regard to fluoxetine, exactly half of the double-blind studies [21,23] 
have found some utility in the prescription of this compound for negative symptoms of 
schizophrenia, while the other half (which are also the most recent studies) [24, 25] did not 
show the usefulness of this drug in the management of the disorder. Regarding sertraline, the 
results of studies agree in the non-effectiveness of the compound on negative symptoms of 
schizophrenia, with results rather contradictory concerning depressive symptoms. Similar 
considerations may be done for citalopram which, however, might have some utility for 
prevention of suicide in schizophrenia patients [45], although long-term prospective studies 
have to confirm preliminary evidence. Few studies investigated escitalopram for the treatment 
of schizophrenia: no evidence of efficacy resulted for negative and depressive symptoms, but 
the compound might be useful in case of obsessive-compulsive symptoms, although, again, 
double-blind studies have to replicate the results of a small sample size open-label study [49]. 
Most studies indicate that fluvoxamine may improve negative symptoms of schizophrenia, but 
the most recent study with the largest sample of schizophrenia patients disconfirms the first 
positive results [76]. Furthermore, one of the double-blind studies reported a very slight 
advantage of fluvoxamine over placebo on negative symptoms of schizophrenia [65]. With the 
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exclusion of two case reports [74, 75], available preliminary data agree in showing the 
effectiveness of augmentative fluvoxamine (100-200 mg/day) to antipsychotics for obsessive-
compulsive symptoms of schizophrenia patients. Finally, fluvoxamine has currently no 
evidence of efficacy for depressive symptoms in schizophrenia. Three open-label studies [80, 
81,83] and one double-blind trial [82] for a total of 95 patients with schizophrenia show the 
effectiveness of paroxetine on negative symptoms of schizophrenia, but more evidence is 
needed to define the usefulness of this molecule in the treatment of these patients. On the other 
hand, current data do not support the use of this compound for ameliorating depressive 
symptoms of schizophrenia subjects. 
Taken as a whole, current evidence prevents from recommending the use of SSRIs for the 
treatment of schizophrenia patients, since even the few favourable results (e.g. fluvoxamine for 
obsessive symptoms) come from studies with a limited number of patients. 
 
11. EXPERT OPINION 
Only preliminary considerations can be made about the effectiveness of SSRIs on different 
psychopathological dimensions of schizophrenia 
Regarding the negative symptoms, no evidence of efficacy is currently available for 
sertraline, citalopram and escitalopram. With regard to fluoxetine and fluvoxamine results are 
mixed, while the paroxetine may actually have some efficacy on negative symptoms of 
schizophrenia. The data on the use of paroxetine on negative symptoms of schizophrenia are 
predominantly from open-label studies with limited samples, but the effect sizes are higher than 
those associated with atypical antipsychotics (d=0.97-1.56 versus 0.58). These positive results 
of paroxetine on negative symptoms of schizophrenia may be due to its specific 
pharmacodynamic properties: its action as a noradrenaline reuptake inhibitor at medium to high 
doses (those used in most studies) [87] and its anticholinergic effects, which could improve 
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parkinsonism and negative symptoms associated with the use of first-generation antipsychotics 
[88]. With very few exceptions [23, 43], there is no evidence of the effectiveness of SSRIs on 
depressive symptoms of schizophrenia: this observation may reflect different biological 
mechanisms underlying major depression compared with depressive symptoms in 
schizophrenia [89]. Depressive symptoms affect about 20% of schizophrenia patients [90] and a 
similar percentage of patients take antidepressant medications [91]; furthermore a quite recent 
systematic review about instruments to measure depressive symptoms in schizophrenia patients 
concluded that the CDSS was the most appropriate tool to rate depression in schizophrenia [92]. 
In addition, the CDSS is even more specific to detect depressive symptoms during acute 
exacerbations of schizophrenia [93]. Despite the appropriateness of the CDSS, most studies 
about depression and schizophrenia use other rating scales (e.g. MADRS), including those 
about the effectiveness of SSRIs in acute schizophrenia symptoms. In this way the results about 
the effects of SSRIs on depressive symptoms of schizophrenia must be interpreted in the light 
of the use of tools not always adequate for the measurement of depression in schizophrenia 
(table 3). SSRIs may have some utility on obsessive symptoms of schizophrenia, but studies are 
few and they have so limited samples that it is not possible to draw any reliable conclusion. The 
effect of SSRIs on other aspects of schizophrenia such as impulsivity, suicidal ideation, 
cognition and global functioning was studied sporadically so that it is impossible to give even a 
preliminary opinion about these topics (table 4). 
We must keep in mind that in all studies SSRIs are combined with antipsychotics and this 
may result in variations of drug plasma concentrations. This has two key clinical implications: 
first, there may be an increase of side effects (e.g. QT interval prolongation) [94] and, second, a 
decrease of antidepressant effectiveness. Fatal clozapine overdose has been reported in one 
patient treated with a combination of the antipsychotic and fluoxetine [95]. In addition, sudden 
cardiac death resulted by the combination of clozapine (200 mg/day), risperidone (6 mg/day) 
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and sertraline (200 mg/day) in a young paranoid schizophrenia patient [96]. Exacerbation of 
idiopathic priapism may be the effect of risperidone-sertraline [97] or risperidone-citalopram 
[98] combinations. Paroxetine may impair the elimination of risperidone by inhibition of 
cytochrome CYP2D6 with the possibility to develop parkinsonism [99]. An incipient 
neuroleptic malignant syndrome was observed in a young paranoid schizophrenia patient with 
quetiapine/paroxetine combination treatment [100]. Co-administration of fluvoxamine increases 
plasma concentrations of clozapine [101] with the likely increase of agranulocytosis, seizures, 
extrapyramidal symptoms [102] and clozapine-associated obsessive-compulsive symptoms [75]. 
Combination of fluvoxamine with olanzapine has been reported to be associated with increased 
tremor and rigidity [103]. From a pharmacokinetic point of view, citalopram and escitalopram 
are hypothetically the most suitable SSRIs to combine with antipsychotics for their poor 
interaction with cytochromes [104], however a case of urinary obstruction has been reported as 
a consequence of the combination of aripiprazole and citalopram [105]. 
Future studies should take into account the following observations to get a more precise 
evaluation of the use of SSRIs in schizophrenia: 
1) it is not always precisely defined in the studies if certain symptoms are part of 
schizophrenia or are the result of comorbid psychiatric conditions such as obsessive-compulsive 
disorder [106-108]; 
2) trials should use appropriate rating scales for the evaluation of the different clinical 
dimensions of schizophrenia in order to allow pooled analyses and meta-analytical approaches 
of large samples of patients; 
3) most of available studies are underpowered: researches with large samples are required to 
obtain more reliable data; 
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4) clinical aspects need to be monitored for an extended period of time to verify if the 
efficacy of SSRIs in schizophrenia is sustained in the long-term and to ascertain possible 
iatrogenic causes of psychotic symptoms; 
5) combined treatments might be associated with potential dangerous side effects and future 
studies should quantify the risk/benefit ratio of antipsychotic/antidepressant concomitant 
administration in schizophrenia patients; 
6) pharmacokinetic interactions should be monitored in the long-term, measuring drug 
plasma levels regularly 
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Table 1. Selective Serotonin Reuptake Inhibitors (SSRIs) and Schizophrenia: Summary of Studies  
Paper Molecule Double-
Blind 
Sample Primary Outcomes Effect sizes (r/d) 
Goff et al., 1990 [17] 
 
Fluoxetine (20 mg/day) No N=14 
(1 SKA) 
BPRS score reduction 
(compared to baseline) 
0.65/1.7 
NSS score reduction 
(compared to baseline) 
0.41/0.9 
HAM-D score reduction 
(compared to baseline) 
0.29/0.6 
GAS score improvement 
(compared to baseline) 
0.41/0.91 
Spina et al., 1994 [21] Fluoxetine (20 mg/day) Yes N=30 SANS score reduction 
(compared to placebo) 
0.54/1.28 
Goff et al., 1995 [23] Fluoxetine (20 mg/day) Yes N=41 
(3 SKA) 
BPRS score reduction 
(compared to placebo) 
N.S.       0.17/0.34 
BPRS negative score reduction 
(compared to placebo) 
 0.34/0.73 
HAM-D score reduction 
(compared to placebo) 
N.S.       0.16/0.32 
GAS score improvement 
(compared to placebo) 
N.S.       0.06/0.12 
Buchanan et al., 1996 [24] Fluoxetine (20-80 
mg/day) 
Yes N=33 BPRS positive score reduction 
(compared to placebo) 
N.S.       0.16/0.33 
SANS score reduction 
(compared to placebo) 
N.S.        0.23/0.47 
HAM-D score reduction 
(compared to placebo) 
N.S.        0.10/0.21 
HAM-D obsession item score 
reduction (compared to 
placebo) 
N.S.       0.24/0.49 
Arango et al., 2000 [25] Fluoxetine (36.2 
mg/day) 
Yes N=27 BPRS positive score reduction 
(compared to placebo) 
N.S.       0.19/0.38 
BPRS negative score reduction 
(compared to placebo) 
N.S.        0.03/0.06 
SANS score reduction 
(compared to placebo) 
N.S.        0.19/0.38 
HAM-D score reduction 
(compared to placebo) 
N.S.       0.19/0.38 
Agarwal and Agarwal, 2000 [26] Fluoxetine (80 mg/day) No N=7 YBOCS score reduction 
(compared to baseline) 
0.69/1.92 
Shim et al., 2003 [27] Fluoxetine (20-60 
mg/day) 
No N=15 PANSS score reduction 
(compared to baseline) 
0.53/1.24 
Kirli and Caliskan, 1998 [33] Sertraline (50 mg/day) Yes N=40 “Good” or “Very Good” 
efficacy (compared to 
imipramine 150 mg/day) 
0.22/0.45 
Lee et al., 1998 [34] Sertraline (50 mg/day) Yes N=36 PANSS positive score 
reduction (compared to 
placebo) 
N.S.       0.12/0.25 
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PANSS negative score 
reduction (compared to 
placebo) 
N.S.        <0.01/0.01 
PANSS general score 
reduction (compared to 
placebo) 
N.S.        0.03/0.05 
CGI-S  score reduction 
(compared to placebo) 
N.S.       0.06/0.13 
Addington et al., 2002 [35] Sertraline (50-100 
mg/day) 
Yes N=48 
(4 SKA) 
CDSS score at endpoint 
(compared to placebo) 
N.S.      0.015 /0.03 
HAM-D score at endpoint 
(compared to placebo) 
N.S.      0.03/0.06  
Mulholland et al., 2003 [36] Sertraline (till 100 
mg/day) 
Yes  N=26 BDI score reduction 
(compared to placebo) 
N.S.        0.1/0.2 
HAM-D score reduction 
(compared to placebo) 
N.S.        0.24/0.5 
BPRS score reduction 
(compared to placebo) 
N.S.       0.37/0.8 
BPRS Depression  Item score 
reduction (compared to 
placebo) 
N.S.       0.37/0.79 
BPRS Anxiety Depression 
Factor score reduction 
(compared to placebo) 
0.55/1.3 
SANS score reduction 
(compared to placebo) 
N.S.        0.12/0.25 
Vartiainen et al., 1995 [40] Citalopram (20-60 
mg/day) 
Yes N=15 SOAS scores at endpoint 
(compared to placebo) 
N.S.        0.10/0.21 
BPRS scores at endpoint 
(compared to placebo) 
N.S.        0.23/0.47 
SDAS scores at endpoint 
(compared to placebo) 
N.S.        0.3/0.63 
GAS scores at endpoint 
(compared to placebo) 
N.S.        0.25/0.51 
CGI-S scores at endpoint 
(compared to placebo) 
N.S.        0.1/0.2 
Salokangas et al., 1996 [41] Citalopram (till 40 
mg/day) 
Yes  N=90 PANSS score reduction 
(compared to placebo) 
N.S.        0.1/0.2 
Kasckow et al., 2001 [43] Citalopram (20-40 
mg/day) 
No N=19 HAM-D score reduction 
(compared to placebo) 
0.76/2.33 
CGI-S score reduction 
(compared to placebo) 
0.6/1.51 
PANSS score reduction 
(compared to placebo) 
N.S.       0.48/1.1 
Friedman et al., 2005 [44] Citalopram (40 mg/day) Yes N=19 PANSS positive score 
reduction (compared to 
placebo) 
N.S.       0.18/0.36 
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PANSS negative score 
reduction (compared to 
placebo) 
N.S.       0.11/0.23 
 
PANSS general score 
reduction (compared to 
placebo) 
N.S.       0.21/0.43 
Haukka et al., 2008 [45] Citalopram No N=1611 Rate of suicides in citalopram 
users (compared to non-
antidepressant users) 
0.20/0.42 
Hinkelmann et al., 2013 [46] Citalopram (30 mg/day)  Yes N=51 PANSS negative score 
reduction (compared to 
placebo) 
N.S.       0.1/0.21 
HAM-D score reduction 
(compared to placebo) 
N.S.       0.14/0.28 
Usall et al., 2014 [47] Citalopram (30 mg/day) Yes N=90 PANSS negative score 
reduction (compared to 
placebo) 
N.S.       0.09/0.19 
 
SANS score reduction 
(compared to placebo) 
N.S.       0.06/0.13 
Iancu et al., 2010 [48] Escitalopram (20  
mg/day) 
Yes N=40 PANSS score reduction 
(compared to placebo) 
N.S.        0.19 /0.39 
PANSS negative score 
reduction (compared to 
placebo) 
N.S.        0.18/0.36 
SANS score reduction 
(compared to placebo) 
N.S.        0.19 /0.39 
SFS score change (compared 
to placebo) 
N.S.        0.14/0.29 
HAM-D score reduction 
(compared to placebo) 
N.S.        0.09 /0.18 
Stryjer et al., 2013 [49] Escitalopram (20  
mg/day) 
No N=15 YBOCS score reduction 
(compared to baseline) 
0.33/0.7 
Silver et al., 1992 [52] Fluvoxamine (50-100 
mg/day) 
Yes N=30 SANS score reduction 
(compared to placebo) 
0.40/0.86 
Silver et al., 1996 [59] Fluvoxamine (25-100 
mg/day) 
No N=8 BPRS scores at endpoint 
(compared to baseline) 
0.36/0.78 
BPRS positive scores at 
endpoint (compared to 
baseline) 
N.S.       0.02 /0.04 
BPRS negative scores at 
endpoint (compared to 
baseline) 
               0.39/0.85 
SANS scores at endpoint 
(compared to baseline) 
N.S.        0.23 /0.47 
Silver and Shmugliakov, 1998 
[61] 
Fluvoxamine (100 
mg/day) 
Yes N=25 SANS score reduction 
(compared to maprotiline) 
0.21/0.42 
BPRS negative score reduction 
(compared to maprotiline) 
0.25/0.51 
MADRS N.S.       0.21/0.42 
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Reznik and Sirota, 2000 [63] Fluvoxamine (100-200 
mg/day) 
Yes N=30 YBOCS score reduction 
(compared to placebo) 
0.39/0.85 
PANSS negative score 
reduction (compared to 
placebo) 
N.S.       0.18/0.36 
CGI-I change (compared to 
placebo) 
N.S.       0.18/0.36 
Reznik and Sirota, 2000 [64] Fluvoxamine (100-200 
mg/day) 
No N=16 YBOCS score reduction 
(compared to baseline) 
0.59/1.45 
BPRS negative score reduction 
(compared to baseline) 
0.64/1.67 
Silver et al., 2000 [65] Fluvoxamine (50-100 
mg/day) 
Yes N=52 SANS score reduction 
(compared to placebo) 
0.14/0.28 
Hiemke et al., 2002 [67] Fluvoxamine (100 
mg/day) 
No N=8 CDSS score reduction 
(compared to baseline) 
N.S.       0.44/0.98 
Lu et al., 2002 [69] Fluvoxamine (50-100 
mg/day) 
No N=12 CGI-S score reduction 
(compared to baseline) 
               0.65/1.71 
GAF change (compared to 
baseline) 
   0.71/2.01 
Takahashi et al., 2002 [68] Fluvoxamine (100 
mg/day) 
No N=30 PANSS positive score 
reduction (compared to 
baseline) 
N.S.       0.12/0.24 
PANSS negative score 
reduction (compared to 
baseline) 
N.S.       0.14/0.29 
PANSS  general score 
reduction (compared to 
baseline) 
N.S.       0.13/0.26 
Yasui-Furukori et al., 2004 [70] Fluvoxamine (till 150 
mg/day) 
No N=12 BPRS positive score reduction 
(compared to baseline) 
N.S.       <0.01/0.01 
BPRS negative score reduction 
(compared to baseline) 
0.5/1.16 
Chaichan, 2004 [72]  Fluvoxamine 50 
mg/day 
No N=20 BPRS total score reduction 
(compared to placebo) 
0.37/0.79 
BPRS positive score reduction 
(compared to placebo) 
0.26/0.54 
BPRS negative score reduction 
(compared to placebo) 
N.S.       0.045/0.09 
Niitsu et al., 2012 [76] Fluvoxamine (150 
mg/day) 
Yes N=48 PANSS score reduction 
(compared to placebo) 
N.S.       0.27/0.55 
SANS score reduction 
(compared to placebo) 
N.S.       0.07/0.15 
MADRS score reduction 
(compared to placebo) 
N.S.       0.15/0.31 
Jockers-Scherübl et al., 2005 [82] Paroxetine (30 mg/day) Yes N=25 PANSS negative score 
reduction (compared to 
placebo) 
0.44/0.97 
HAM-D score reduction 
(compared to placebo) 
N.S.       0.035/0.07 
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Saito et al., 2005 [81] Paroxetine (till 40 
mg/day) 
No N=12 PANSS negative score 
reduction (compared to 
baseline) 
0.62/1.56 
PANSS depression score 
reduction (compared to 
baseline) 
N.S.       0.15/0.3 
CDSS score reduction 
(compared to baseline) 
N.S.       0.33/0.7 
Nemoto et al., 2012 [84] Paroxetine (20 mg/day) No N=14 CGI-S score reduction 
(compared to baseline)  
N.S.       0.17/0.35 
 
 
Legend 
BDI: The Beck Depression Inventory 
BPRS: Brief Psychiatric Rating Scale 
CDSS: Calgary Depression Scale for Schizophrenia 
CGI-I: Clinical Global Impression (improvement) 
CGI-S: Clinical Global Impression (severity of illness)  
GAF: Global Assessment of Functioning 
GAS: Global Assessment Scale 
HAM-D: Hamilton Depression Rating Scale 
MADRS: Montgomery-Asberg Depression Rating Scale 
NSS: Negative Symptom Scale 
PANSS: Positive and Negative Syndrome Scale 
SANS: Scale for the Assessment of Negative Symptoms 
SDAS: The Social Dysfunction and Aggression Scale 
SFS: Social Functioning Scale 
SKA: Schizoaffective 
SOAS: The Staff Observation Aggression Scale 
YBOCS: Yale Brown Obsessive Compulsive Scale 
 
N.S.: not significant 
 
Note: Case reports or studies for which it was impossible to calculate the effect sizes were not included   
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Table 2. Evaluation of quality of included studies 
Studies Molecule Quality 
Goldman and Janecek, 1990 [16] Fluoxetine 0 
Goff et al., 1990 [17] Fluoxetine  0 
Spina et al., 1994 [21] Fluoxetine ++ 
Bacher et al., 1994 [22] Fluoxetine 0 
Goff et al., 1995 [23] Fluoxetine + 
Buchanan et al., 1996 [24] Fluoxetine ++ 
Arango et al., 2000 [25] Fluoxetine ++ 
Agarwal and Agarwal, 2000 [26] Fluoxetine 0 
Shim et al., 2003 [27] Fluoxetine + 
Thakore et al., 1996 [30] Sertraline 0 
Kirli and Caliskan, 1998 [33] Sertraline + 
Lee et al., 1998 [34] Sertraline ++ 
Addington et al., 2002 [35] Sertraline ++ 
Mulholland et al., 2003 [36] Sertraline ++ 
Vartiainen et al., 1995 [40] Citalopram + 
Salokangas et al., 1996 [41] Citalopram ++ 
Taiminen et al., 1997 [42] Citalopram + 
Kasckow et al., 2001 [43] Citalopram + 
Friedman et al., 2005 [44] Citalopram + 
Haukka et al., 2008 [45] Citalopram + 
Hinkelmann et al., 2013 [46] Citalopram + 
Usall et al., 2014 [47] Citalopram ++ 
Iancu et al., 2010 [48] Escitalopram ++ 
Stryjer et al., 2013 [49] Escitalopram 0 
Silver et al., 1992 [52] Fluvoxamine ++ 
Silver et al., 1996 [59] Fluvoxamine + 
Szegedi et al., 1999 [60] Fluvoxamine + 
Silver and Shmugliakov, 1998 [61] Fluvoxamine ++ 
Poyurovsky et al., 1999 [62] Fluvoxamine + 
Reznik and Sirota, 2000 [63] Fluvoxamine ++ 
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Reznik and Sirota, 2000 [64] Fluvoxamine + 
Silver et al., 2000 [65] Fluvoxamine ++ 
Hiemke et al., 2002 [67] Fluvoxamine + 
Lu et al., 2002 [69] Fluvoxamine 0 
Takahashi et al., 2002 [68] Fluvoxamine + 
Yasui-Furukori et al., 2004 [70] Fluvoxamine 0 
Chaichan, 2004 [72] Fluvoxamine 0 
Niitsu et al., 2012 [76] Fluvoxamine ++ 
Jockers-Scherübl et al., 2001 [80] Paroxetine + 
Jockers-Scherübl et al., 2005 [82] Paroxetine ++ 
Saito et al., 2005 [81] Paroxetine + 
Rusconi et al., 2009 [83]  Paroxetine + 
Nemoto et al., 2012 [84] Paroxetine  0 
 
 
Legend for quality of studies 
Each + corresponds with one of these criteria: 
1) Sample size > 100 
2) Double-blinded design  
3) Administration of specific rating scales to assess schizophrenia symptoms in relation to 
primary study outcomes (The Calgary Depression Scale for Schizophrenia, The Positive and 
Negative Syndrome Scale,  The Scale for the Assessment of Negative Symptoms) 
0: none of the above criteria 
Note: 
Case reports have not been reported in the present table 
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Table 3. Summary of results and appropriateness of assessment about the use of SSRIs for 
depressive symptoms in schizophrenia 
Studies Molecule CDSS 
use 
Improvement of depressive 
symptoms 
Goff et al., 1990 [17] 
 
Fluoxetine  No Yes 
Spina et al., 1994 [21] Fluoxetine No Yes 
Bacher et al., 1994 [22] Fluoxetine No No 
Goff et al., 1995 [23] Fluoxetine No  No 
Buchanan et al., 1996 [24] Fluoxetine No No 
Arango et al., 2000 [25] Fluoxetine No No 
Kirli and Caliskan, 1998 [33] Sertraline No Yes 
Addington et al., 2002 [35] Sertraline Yes No 
Mulholland et al., 2003 [36] Sertraline No No 
Taiminen et al., 1997 [42] Citalopram No Yes (depression/anxiety dimension 
of PANSS), No (HAM-D scores) 
Kasckow et al., 2001 [43] Citalopram No Yes 
Hinkelmann et al., 2013 [46] Citalopram No No 
Iancu et al., 2010 [48] Escitalopram No No 
Silver and Shmugliakov, 1998 [61] Fluvoxamine No No 
Hiemke et al., 2002 [67] Fluvoxamine Yes No 
Niitsu et al., 2012 [76] Fluvoxamine No No 
Jockers-Scherübl et al., 2001 [80] Paroxetine No Yes 
Jockers-Scherübl et al., 2005 [82] Paroxetine No No 
Saito et al., 2005 [81] Paroxetine Yes No 
 
Legend  
CDSS: The Calgary Depression Scale for Schizophrenia 
PANSS: The Positive and negative Syndrome Scale 
HAM-D: Hamilton Depression Rating Scale 
Note: Case reports have not been reported 
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Table 4. Summary of the effects of SSRIs in schizophrenia according to psychopathological 
dimensions  
Psychopathological 
dimension 
Compound Positive Results Negative Results 
Negative Fluoxetine 1 open-label study (N=14) and 2 
double-blind studies (N=71) 
2 double-blind studies (N=60) 
Sertraline 1 open-label study (N=20) 2 double-blind studies  (N=62) 
Citalopram No studies 3 double-blind studies (N=160) 
Escitalopram No studies 1 double blind study (N=40) 
Fluvoxamine 5 open-label studies (N=62) and 3 
double-blind studies (N=107)  
3 open-label studies (N=58) and 2 
double-blind studies (N=78) 
Paroxetine 2 open-label studies (N=20) and 1 
double-blind study (N=25) 
Fluvoxamine > Paroxetine in 1 
open-label study (N=50) 
Cognitive Fluoxetine No studies No studies 
Sertraline No studies No studies 
Citalopram No studies 1 double-blind study (N=19) 
Escitalopram No studies No studies 
Fluvoxamine No studies 1 double-blind study (N=48) 
Paroxetine No studies No studies 
Depressive Fluoxetine 2 open-label studies (N=44) 1 open label study (N=13) and 3 
double-blind studies (N=101) 
Sertraline 1 double-blind study (N=40) 2 double-blind studies (N=74) 
Citalopram 1 single-blind study (N=19) 1 open-label study (N=51) 
Escitalopram No studies 1 double-blind study (N=40) 
Fluvoxamine No studies 1 open-label study (N=8) and 2 
double-blind studies (N=73)  
Paroxetine 1 open-label study (N=8) 1 open-label study (N=12) and 1 
double-blind study (N=25) 
Impulsive-Aggressive Fluoxetine 1 open-label (N=8)  No studies 
Sertraline No studies No studies 
Citalopram 1 cohort study (N=1611) 1 double-blind study (N=15) 
Escitalopram No studies No studies 
Fluvoxamine No studies No studies 
Paroxetine No studies No studies 
Obsessive-Compulsive Fluoxetine 1 open-label study (N=7) 1 double-blind study (N=33) 
Sertraline No studies No studies 
Citalopram No studies No studies 
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Escitalopram 1 open-label study No studies 
Fluvoxamine 2 open-label studies (N=26) and 1 
double-blind study (n=30) 
No studies 
Paroxetine No studies No studies 
 
 
Note: The sum of sample sizes of studies are reported into brackets. Case reports have not 
been reported 
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Figure 1. Prisma Diagram for systematic reviews 
Titles and abstracts screened 
N=513 
Excluded: N=437 
Animal studies: n=26 
Review: n=394 
Meta-analyses: n=6 
Improvement of medical 
conditions:  n=11 
Full-text article screened 
N=76 
Included articles 
N=69 
Excluded: N=7 
Mixed samples: n=5 
Articles not in English: n=2 
Initial Search 
N=675 
Duplicates: n=162 
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